Abstract 4718: ABBV-075, a novel BET family bromodomain inhibitor, represents a promising therapeutic agent for a broad spectrum of cancer indications
Aparna V. Sarthy(Abbott Fund), Yu Shen(University of Florida), Daniel H. Albert(AbbVie (United States)), Fritz G. Buchanan(AbbVie (United States)), Lisa Hasvold(AbbVie (United States)), Lloyd T. Lam(National Institutes of Health), Keith F. McDaniel(AbbVie (United States)), Tamar Uziel(AbbVie (United States)), Paul Tapang(AbbVie (United States)), Dachun Liu(Kunming University of Science and Technology), Leiming Li(First Hospital of China Medical University), Ganesh Rajaraman(AbbVie (United States)), W. H. Scott(AbbVie (United States)), George S. Sheppard(AbbVie (United States)), Paul Hessler(AbbVie (United States)), Emily J. Faivre(AbbVie (United States)), Warren M. Kati(AbbVie (United States)), John K. Pratt(AbbVie (United States)), Xiaoyu Lin(AbbVie (United States)), Le Wang(AbbVie (United States)), Xiaoli Huang(Sichuan Agricultural University), Mai H. Bui(AbbVie (United States)), Steven W. Elmore(AbbVie (United States)), Steve Fidanze(AbbVie (United States)), Guowei Fang(Affiliated Hospital of Shandong University of Traditional Chinese Medicine), Saul H. Rosenberg(Abbott Fund), Denise M. Wilcox(AbbVie (United States)), Terry Magoc(AbbVie (United States))
Cited by 10
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
|Cancer Research|2008|2k
Requirement of the MRN complex for ATM activation by DNA damage
|The EMBO Journal|2003|1.1k
Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways
|Proceedings of the National Academy of Sciences|2008|985